• If you are wondering whether Edwards Lifesciences at around US$80.99 is a fair deal or a stretched price, the starting point is understanding how its current market value stacks up against several valuation checks.
• The share price has moved 4.0% over the last 7 days, while returns for the past month and year to date sit at 2.0% decline and 5.1% decline. A 13.2% gain over the last year adds an extra layer to the current pricing question.
• Recent coverage has focused on Edwards Lifesciences as a key medical technology name, which helps explain why investors continue to reassess what they are prepared to pay for its shares. Broader commentary around medical equipment companies has also kept attention on how these businesses are valued in the market.
• On Simply Wall St's 6 point valuation framework, Edwards Lifesciences currently scores 1 out of 6. The next step is to look at how different valuation methods arrive at that score and then consider an even richer way to think about value that comes later in this article.

Edwards Lifesciences scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Edwards Lifesciences Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and discounting them back to a present value using a required rate of return.

For Edwards Lifesciences, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow (FCF) is about $1.29b. Analyst estimates and subsequent extrapolations suggest FCF of $1.55b in 2026, $2.06b in 2028 and $3.17b by 2035, with part of the later years based on Simply Wall St estimates rather than direct analyst forecasts.

When these projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $88.29 per share. Compared to a current share price of around $80.99, the DCF implies the stock is 8.3% undervalued, which is a relatively small gap.

Result: ABOUT RIGHT

Edwards Lifesciences is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Edwards Lifesciences Price vs Earnings

For profitable companies like Edwards Lifesciences, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. It links directly to how quickly earnings might grow and how predictable they are, which is what most investors focus on when judging value.

In general, higher growth expectations and lower perceived risk support a higher “normal” or “fair” P/E, while slower growth and higher risk justify a lower one. Edwards Lifesciences currently trades on a P/E of about 44.0x. That is higher than the Medical Equipment industry average of around 25.8x and also above a peer group average of roughly 27.1x, so the stock is priced at a premium compared with these broad benchmarks.

Simply Wall St’s Fair Ratio is a proprietary estimate of what the P/E could be given factors such as earnings growth, profit margins, industry, market cap and specific risks. This tends to be more tailored than a simple comparison with peers or sector averages, which do not adjust for company specific strengths or weaknesses. For Edwards Lifesciences, the Fair Ratio is 32.8x, which is below the current P/E of 44.0x and indicates the shares trade at a richer multiple than this framework would suggest.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Edwards Lifesciences Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as simple stories that link your view on Edwards Lifesciences to a set of numbers, connecting assumptions about future revenue, earnings, margins and a fair value back to today’s share price.

On Simply Wall St’s Community page, Narratives are an accessible tool used by millions of investors. They help you spell out your thesis, translate it into a forecast and a fair value, then compare that fair value with the current price to decide whether the stock looks attractive, fully priced or expensive based on your own expectations.

Narratives are updated automatically when fresh information such as earnings, news or guidance is added to the platform. This means your story and fair value stay aligned with the latest data rather than becoming stale.

For Edwards Lifesciences, for example, a more upbeat Narrative might anchor around the US$110 analyst target that assumes certain growth in revenue, earnings of about US$2.0b by 2029 and a P/E of 33.9x. A more cautious Narrative might lean closer to the US$84 target, showing how two investors can look at the same company and reach very different but clearly explained valuations.

Do you think there's more to the story for Edwards Lifesciences? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.